Belite Bio Inc ADR Total Liabilities
Belite Bio Inc ADR total liabilities. Based on the latest financial reports, Belite Bio Inc ADR (BLTE) has total liabilities worth $14.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Belite Bio Inc ADR's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Belite Bio Inc ADR (2020–2025)
Total liabilities of Belite Bio Inc ADR from 2020 to 2025. This chart illustrates how Belite Bio Inc ADR's total liabilities have evolved over time, based on quarterly financial data. Explore Belite Bio Inc ADR (BLTE) investment intensity to see how much of total assets are deployed in long-term investments.
Belite Bio Inc ADR Competitors by Total Liabilities
The table below lists competitors of Belite Bio Inc ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Accelleron Industries AG
SW:ACLN
|
Switzerland | CHF1.06 Billion |
|
B2Gold Corp
TO:BTO
|
Canada | CA$2.25 Billion |
|
Dongxing Sec Co Ltd
SHG:601198
|
China | CN¥86.75 Billion |
|
XP Inc
F:XP9
|
Germany | €372.98 Billion |
|
Janus Living, Inc.
NYSE:JAN
|
USA | $1.01 Billion |
|
LIG Nex1 Co Ltd
KO:079550
|
Korea | ₩7.12 Trillion |
|
ESCO Technologies Inc
NYSE:ESE
|
USA | $771.13 Million |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥16.71 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Belite Bio Inc ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Belite Bio Inc ADR (BLTE) total assets.
Liquidity & Leverage Metrics
Belite Bio Inc ADR Total Liabilities Ratios Explained
Belite Bio Inc ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 33.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Belite Bio Inc ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Belite Bio Inc ADR (2020–2025)
The table below shows the annual total liabilities of Belite Bio Inc ADR from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.07 Million | +59.56% |
| 2024-12-31 | $6.31 Million | +49.87% |
| 2023-12-31 | $4.21 Million | +51.91% |
| 2022-12-31 | $2.77 Million | -91.71% |
| 2021-12-31 | $33.44 Million | +2.02% |
| 2020-12-31 | $32.78 Million | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more